COX2 inhibitor NS398 reduces HT-29 cell invasiveness by modulating signaling pathways mediated by EGFR and HIF1-α

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1793-1800

  Bocca, Claudia ^a   Bozzo, Francesca ^a   Miglietta, Antonella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

COX2; EGFR; HT 29; Hypoxia; Invasiveness

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; SULFONAMIDE;

ARTICLE; CELL INVASION; CELL PROLIFERATION; COLON CANCER; HT 29 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ZYMOGRAPHY; CELL HYPOXIA; CELL MOTION; CELL SURVIVAL; COX2; DRUG EFFECT; EGFR; EPITHELIAL MESENCHYMAL TRANSITION; HT-29; HYPOXIA; INVASIVENESS; METABOLISM; TUMOR CELL LINE;

COX2; EGFR; HT-29; HYPOXIA; INVASIVENESS;

CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLOOXYGENASE 2 INHIBITORS; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; HT29 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NITROBENZENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84902261217     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Roxburgh C, McDonald A, Salmond J, Oien K, Anderson J, McKee R, Horgan P and McMillan D: Adjuvant chemotherapy for resected colon cancer: Comparison of the prognostic value of tumour- and patient-related factors. Int J Colorectal Dis 26: 483-492, 2011.
2. Kenny PA, Lee GY and Bissell MJ: Targeting the tumor microenvironment. Front Biosci 12: 3468-3474, 2007.
3. Misra A, Pandey C, Sze SK and Thanabalu T: Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT). PLoS One 7: 10.1371/journal.pone.0049766, 2012.
4. Baas JM, Krens LL, Guchelaar HJ, Morreau H and Gelderblom H: Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: A review. Oncologist 16: 1239-1249, 2011.
5. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
6. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA: Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007.
7. Castellano E and Downward J: RAS Interaction with PI3K: More than just another effector pathway. Genes Cancer 2: 261-274, 2011.
8. Giaccia A, Siim BG and Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811, 2003.
9. Kikuchi H, Pino MS, Zeng M, Shirasawa S and Chung DC: Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1α and -2α in colon cancer. Cancer Res 69: 8499-8506, 2009.
10. Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L and Zhang Y: Clinicopathologic significance of HIF-1α, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol 2010: doi10.1155/2010/537531, 2010
11. Mook OR, Frederiks WM and Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705: 69-89, 2004.
12. Guarino M, Rubino B and Ballabio G: The role of epithelial mesenchymal transition in cancer pathology. Pathology 39: 305-318, 2007.
13. Zhong H, Willard M and Simons J: NS398 reduces hypoxia-inducible factor (HIF)-1α and HIF-1 activity: multiple-level effects involving cyclooxygenase-2-dependent and -independent mechanisms. Int J Cancer 112: 585-95, 2004.
14. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C and Kaidi A: The COX2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386, 2009.
15. Leone V, Di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM, Iuliano F and Acquaviva AM: PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through RAS-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 293: G673-G681, 2007.
16. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM, Morrow JD and Capdevila JH: Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 279: 29797-29804, 2004.
17. Bozzo F, Bassignana A, Lazzarato L, Boschi D, Gasco A, Bocca C and Miglietta A: Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. Chem Biol Interact 182: 183-190, 2009.
18. 2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8: 289-293, 2002.
19. Jiang J, Tang YL and Liang XH: EMT: A new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11: 714-723, 2011.
20. Bocca C, Bozzo F, Ievolella M and Miglietta A: A novel nitrooxy substituted analogue of rofecoxib reduces human colon cancer cell growth. Mol Cell Biochem 361: 105-110, 2012.
21. Cannito S, Novo E, Compagnone A, Valfrè di Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A, Bozzo F, Cravanzola C, Bravoco V, Colombatto S and Parola M: Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 29: 2267-2278, 2008.
22. Bocca C, Bozzo F, Cannito S, Parola M and Miglietta A: Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. Mol Carcinog 51: 783-795, 2012.
23. Jing SW, Wang YD, Kuroda M, Su JM, Sun GG, Liu Q, Cheng YJ and Yang CR: HIF-1α contributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP2 expression. Acta Med Okayama 66: 399-407, 2012.
24. Miglietta A, Toselli M, Ravarino N, Vencia W, Chiecchio A, Bozzo F, Motta M, Torchio B and Bocca C: COX2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers. Expert Opin Ther Targets 14: 655-664, 2010.
25. Shono T, Tofilon PJ, Bruner JM, Owolabi O and Lang FF: Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61: 4375-4381, 2001.
26. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
27. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H and Sinicrope FA: Prognostic effect of activated EGFR expression in human colon carcinomas: Comparison with EGFR status. Br J Cancer 102: 165-172, 2010.
28. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 278: 35451-35457, 2003.
29. Wang JY, Chen BK, Wang YS, Tsai YT, Chen WC, Chang WC, Hou MF, Wu YC and Chang WC: Involvement of store-operated calcium signaling in EGF-mediated COX2 gene activation in cancer cells. Cell Signal 24: 162-169, 2012.
30. Sabri A, Ziaee AA, Ostad SN, Alimoghadam K and Ghahremani MH: Crosstalk of EGF-directed MAPK signalling pathways and its potential role on EGF-induced cell proliferation and COX2 expression in human mesenchymal stem cells. Cell Biochem Funct 29: 64-70, 2011.
31. Brown JR and DuBois RN: COX2: A molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855, 2005.
32. Jiang BH and Liu LZ: PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta 1784: 150-158, 2008.
33. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM and McCubrey JA: RAS/RAF/MEK/ERK and PI3K/PTEN/AKT/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2: 135-164, 2011.
34. Vaish V and Sanyal SN: Role of sulindac and celecoxib in the regulation of angiogenesis during the early neoplasm of colon: Exploring PI3K/PTEN/AKT pathway to the canonical Wnt/β-catenin signaling. Biomed Pharmacother 66: 354-367, 2012.
35. Kaidi A, Qualtrough D, Williams AC and Paraskeva C: Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxiainducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66: 6683-6691, 2006.
36. Kim YM, Park SY and Pyo H: Cyclooxygenase-2 (COX2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX2-overexpressing cancer cells. Mol Cancer Res 7: 1367-1377, 2009.